Trump Team Contacts Google, Meta, Snap Over Online Drug Sales: Report
Former Intel CEO Asks People to Pray and Fast for Employees
Rigetti Computing Skyrockets To Record High As Investor Confidence Soars
Microsoft's Plan to Win the Console War: Make Everything an Xbox
Tesla's Challenges, Rivian's Triumph, And Lucid's Ambitions: This Week In EVs
GenAI Being Adopted at Double the Pace of PCs or Internet
Meta's Llama 3.3 70B Outshines Rivals, Nvidia's Liquid-Cooling Breakthrough, XAI Raises $6B: This Week In AI
NXP Semiconductors, Broadcom Among Deutsche Bank's Chip Stocks for 2025
Musk Fuels Speculation On US Bitcoin Reserve As Crypto Surges
Musk Kicked In More Than a Quarter-Billion Dollars To Trump and GOP
Intel Stock Is Where It Was 27 Years Ago: How The World's Leading Chipmaker Lost The Plot, Thrice
Notable Analyst Calls This Week: Tesla, Kroger and FedEx Among Top Picks
Most Visited Wikipedia Pages In 2024: Trump, Harris, Musk, Swift, Politics And Netflix Dominate List
Amazon Re:Invent Creates Positive Implications for Several Semi, Hardware Stocks
TSLA Stock Rally Since Trump Win Has This Analyst 'Cautious' About EV Giant's Prospects Even As He Maintains 'Very Bullish' Outlook: Here's Why
Tesla Investors Conference: New models will be launched in the first half of 2015, with a full-year sales growth target of 20-30%. Computing power will significantly enhance FSD, and there are no competitors for autonomous driving in Europe and America.
Tesla reiterated that the sales growth target for 2025 is 20-30%, and this growth is based on maximizing the utilization of existing production capacity. The significant improvements in FSD over the past year are attributed to an increase in training computing power, which rose from 20,000 GPUs to about 90,000 GPUs in just 10 months.
The competitors of nvidia have really emerged!
Reasoning calculation becomes the breakthrough, cost-effectiveness advantage is key.
Wall Street 'Froth' Marks Weekly Win, Record High for S&P and Bitcoin Piercing $100K
Weekly Buzz: Now THOSE are records!!
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025